Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis. 2001 Apr 1;32(7):1090-4. Epub 2001 Mar 19.
Bernasconi NL, Traggiai E, Lanzavecchia A Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002 Dec 13;298(5601):2199-202.
Chavan S, Bennuri B, Kharbanda M, Chandrasekaran A, Bakshi S, Pahwa S Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus. J Infect Dis. 2001 May 15;183(10):1445-54. Epub 2001 Apr 13.
Crotty S, Ahmed R Immunological memory in humans. Semin Immunol. 2004 Jun;16(3):197-203. Review.
de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000 Jul 12;284(2):190-7.
De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis. 2002 Aug 1;186(3):312-20. Epub 2002 Jul 5.
Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003 Dec;4(12):1191-8. Epub 2003 Nov 16.
Lanzavecchia A, Sallusto F Understanding the generation and function of memory T cell subsets. Curr Opin Immunol. 2005 Jun;17(3):326-32. Review.
Melvin AJ, Mohan KM Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics. 2003 Jun;111(6 Pt 1):e641-4.
Moss WJ, Clements CJ, Halsey NA Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81(1):61-70. Epub 2003 Mar 11. Review.
Moss WJ, Cutts F, Griffin DE Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis. 1999 Jul;29(1):106-12.
Nanan R, Rauch A, Kämpgen E, Niewiesk S, Kreth HW A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles. J Gen Virol. 2000 May;81(Pt 5):1313-9.
Newell ML, Brahmbhatt H, Ghys PD Child mortality and HIV infection in Africa: a review. AIDS. 2004 Jun;18 Suppl 2:S27-34. Review.
Sun JC, Bevan MJ Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003 Apr 11;300(5617):339-42.
Sun JC, Williams MA, Bevan MJ CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol. 2004 Sep;5(9):927-33. Epub 2004 Aug 8.
van Els CA, Nanan R T cell responses in acute measles. Viral Immunol. 2002;15(3):435-50. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.